Previous animal model studies have shown PEA to be beneficial in neuroinflammation and provide neuroprotection.
Transcranial Doppler during head-up tilting may be useful for evaluating dizziness.
People with HBV were 76% more likely and those with HCV were 51% more likely to develop PD than people in the comparison group.
A significant association was found between the apnea-hypopnea index and Epworth Sleepiness Scale scores.
Researchers have developed an assay that accurately identifies small quantities of α-synuclein in cerebrospinal fluid.
There were slower declines in health-related quality of life and mobility when exercise was increased by 30 minutes/week.
The US FDA has approved safinamide as adjunctive therapy in Parkinson's disease to increase "on" time
Improvements in excessive daytime sleepiness and daytime alertness were observed in the bright light therapy group.
Neurofilament light chain, a blood biomarker, demonstrated high accuracy for distinguishing atypical parkinsonian disorders from Parkinson's disease.
Comorbid psychological conditions affect cognitive function in Parkinson's disease, and treatment can be complicated by overlapping symptoms.
New findings suggest that dysregulation of mitochondrial DNA homeostasis may be a key factor in the pathogenesis of neuronal loss in people with Parkinson's disease.
During cognitive co-activation, the levodopa effect was significantly smaller.
The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.
A combination of age and clinical scores better predicted cognitive impairment than age alone.
Adjunctive treatment with safinamide helps increase "on" time in patients with Parkinson's disease.
Mutated GCH1 gene was associated with a 23% increased risk of Parkinson's disease, especially in men 50 years or younger.
A powdered version of the common treatment may help to relieve "off" periods.
Pharmacologic intervention is the current standard of care for Parkinson's disease, yet medications frequently fail to control some symptoms, including tremor and postural instability.
The researchers found that GBA carriers were at greater risk for dementia and death (hazard ratios, 3.16 and 1.85, respectively) than non-carriers.
Vascular disease can have a negative impact on cognition and motor phenotype in PD.
Cognitive training and tDCS, alone or combined, appear to benefit cognition and QOL in Parkinson's patients
The standard MoCA evaluation was unable to predict decline in fluctuating attention and visual memory.
Over fifty percent of respondents reported using 1 or more alternative therapies.
The 4th World Parkinson Congress takes September 20-23, 2016 in Portland, Oregon.
The pathogenesis of GBA on PD is unclear, although several studies have pointed to disruptions of different molecular pathways that contribute to disease onset.
The potential role of active music therapy in ameliorating motor and nonmotor symptoms of Parkinson's disease (PD) was examined by researchers.
All but one type of statin was associated with a dose-dependent neurprotective benefit against Parkinson's.
According to a 2010 report based on a survey of caregivers of people with DLB, 78% of cases were initially misdiagnosed.
The drug was generally well-tolerated among study participants.
Notably, there was no association found between TBI with LOC and dementia.
Neurology Advisor Articles
- Minocycline May Slow Progression From Clinically Isolated Syndrome to Multiple Sclerosis
- Brain Inflammation Observed in Obsessive-Compulsive Disorder
- Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease
- Growing Old Without Alzheimer's Pathology: What's the Secret?
- Traumatic Brain Injury May Increase Later Risk of Dementia